Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 3Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6

Conditions

Carcinoma, Non-Small-Cell Lung 118Lung Neoplasms 51Triple Negative Breast Neoplasms 35Breast Neoplasms 33Small Cell Lung Carcinoma 27Squamous Cell Carcinoma of Head and Neck 25Ovarian Neoplasms 24Fallopian Tube Neoplasms 20Neoplasm Metastasis 19Neoplasms 16Parkinson Disease 4, Autosomal Dominant Lewy Body 15Endometrial Neoplasms 15Head and Neck Neoplasms 14Colorectal Neoplasms 10Carcinoma 10Prostatic Neoplasms 9Oropharyngeal Neoplasms 9Carcinoma, Transitional Cell 9Urinary Bladder Neoplasms 7Esophageal Neoplasms 7Carcinoma, Squamous Cell 7Pancreatic Neoplasms 6Lung Diseases 6Laryngeal Neoplasms 6Carcinoma, Ovarian Epithelial 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Mouth Neoplasms 5Mesothelioma 5Carcinoma, Bronchogenic 5

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5liposomal doxorubicin 4Topotecan 3oregovomab 2olaparib 2niraparib 2fludarabine 2Nivolumab 2Drug Therapy 2Cyclophosphamide 2trastuzumab deruxtecan 1rucaparib 1ribociclib 1pembrolizumab 1palbociclib 1mirvetuximab soravtansine 1isoquercitrin 1irinotecan sucrosofate 1fludarabine phosphate 1anlotinib 1Tinzaparin 1Saline Solution 1Propranolol 1Preoperative Exercise 1Platinum 1Neoadjuvant Therapy 1Music Therapy 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × Carboplatin × 90 days × Clear all
NCT06890338 2026-05-13

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AbbVie

Phase 2 Recruiting
140 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03393884 2026-05-04

OVATION 2

Imunon

Phase 1/2 Active not recruiting
130 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06915025 2026-05-04

OVATION-3

Imunon

Phase 3 Recruiting
500 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04516447 2026-04-07

MUIR

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 1 Recruiting
172 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04498117 2026-04-01

FLORA-5

CanariaBio Inc.

Phase 3 Active not recruiting
615 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04415944 2026-03-19

HIPEC

Wake Forest University Health Sciences

Phase 2 Completed
10 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡